EA201891854A1 - Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m - Google Patents

Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m

Info

Publication number
EA201891854A1
EA201891854A1 EA201891854A EA201891854A EA201891854A1 EA 201891854 A1 EA201891854 A1 EA 201891854A1 EA 201891854 A EA201891854 A EA 201891854A EA 201891854 A EA201891854 A EA 201891854A EA 201891854 A1 EA201891854 A1 EA 201891854A1
Authority
EA
Eurasian Patent Office
Prior art keywords
muscarin
positive allosteric
allosteric modulators
acetyl choline
choline receptor
Prior art date
Application number
EA201891854A
Other languages
English (en)
Inventor
Крейг У. Линдсли
П. Джеффри Конн
Даррен У. Инджерс
Катрина А. Боллинджер
Джули Л. Инджерс
Original Assignee
Вандербилт Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вандербилт Юниверсити filed Critical Вандербилт Юниверсити
Publication of EA201891854A1 publication Critical patent/EA201891854A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Описаны положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора M(mAChR M), фармацевтические композиции, в том числе соединения и способы применения соединений и композиций для лечения неврологических расстройств, психических расстройств или их комбинации.
EA201891854A 2016-02-16 2017-02-16 Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m EA201891854A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662296012P 2016-02-16 2016-02-16
US201662402438P 2016-09-30 2016-09-30
PCT/US2017/018140 WO2017143041A1 (en) 2016-02-16 2017-02-16 Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Publications (1)

Publication Number Publication Date
EA201891854A1 true EA201891854A1 (ru) 2019-01-31

Family

ID=59626207

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891854A EA201891854A1 (ru) 2016-02-16 2017-02-16 Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m

Country Status (15)

Country Link
US (1) US11111251B2 (ru)
EP (1) EP3416639B1 (ru)
JP (1) JP2019504901A (ru)
KR (1) KR20180110132A (ru)
CN (1) CN109069491A (ru)
AU (1) AU2017221404A1 (ru)
BR (1) BR112018016689A2 (ru)
CA (1) CA3014791A1 (ru)
CL (1) CL2018002335A1 (ru)
EA (1) EA201891854A1 (ru)
IL (1) IL261058A (ru)
MA (1) MA44253A (ru)
MX (1) MX2018009952A (ru)
PH (1) PH12018501731A1 (ru)
WO (1) WO2017143041A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2791533C2 (ru) * 2017-06-20 2023-03-09 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6629486B2 (ja) * 2016-09-02 2020-01-15 スヴェン・ライフ・サイエンシズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーター
EA035599B1 (ru) * 2017-04-13 2020-07-14 Сувен Лайф Сайенсиз Лимитед Позитивные аллостерические модуляторы мускариновых m1-рецепторов
HUE063823T2 (hu) * 2017-06-20 2024-02-28 Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként
AU2018289939B2 (en) * 2017-06-20 2022-06-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
IL310346A (en) * 2017-10-20 2024-03-01 Univ Vanderbilt Muscarinic acetylcholine M4 receptor antagonists
EP3700895B1 (en) * 2017-10-27 2021-09-22 Suven Life Sciences Limited Polycyclic amides as muscarinic m1 receptor positive allosteric modulators
KR20200081424A (ko) 2017-10-31 2020-07-07 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
KR20200116945A (ko) 2018-02-02 2020-10-13 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 길항제
WO2019241467A1 (en) * 2018-06-13 2019-12-19 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1
JP7443238B2 (ja) 2018-09-28 2024-03-05 武田薬品工業株式会社 複素環化合物
US20220041581A1 (en) 2018-09-28 2022-02-10 Takeda Pharmaceutical Company Limited Condensed-cyclic compound
EP3643711A1 (en) 2018-10-24 2020-04-29 Bayer Animal Health GmbH New anthelmintic compounds
CA3155864A1 (en) * 2019-10-04 2021-04-08 Vanderbilt University MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4608079A (en) 1983-08-02 1986-08-26 American Cyanamid Company Imidazolidinones, and imidazolidinethiones, process and intermediates for the preparation thereof, and use of said compounds as herbicidal agents
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ES2184705T3 (es) 1999-03-09 2003-04-16 Upjohn Co 4-oxo-4,7-dihidro-tieno(2,3-b)piridina-5-carboxamidas como agentes antivirales.
ATE290000T1 (de) 2000-04-28 2005-03-15 Acadia Pharm Inc Muscarinagonisten
KR100614900B1 (ko) 2001-10-02 2006-08-25 파마시아 앤드 업존 캄파니 엘엘씨 질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
ME02421B (me) * 2009-12-17 2016-09-20 Merck Sharp & Dohme Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida
WO2011159554A1 (en) 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Tetrahydroquinoline amide m1 receptor positive allosteric modulators
EP2709621B1 (en) * 2011-05-17 2016-11-02 Merck Sharp & Dohme Corp. N-linked quinolineamide m1 receptor positive allosteric modulators
WO2015027204A1 (en) 2013-08-23 2015-02-26 Vanderbilt University Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015110370A1 (en) 2014-01-22 2015-07-30 F. Hoffmann-La Roche Ag Fluoro-naphthyl derivatives
US10214508B2 (en) 2014-06-13 2019-02-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016029454A1 (en) 2014-08-29 2016-03-03 Merck Sharp & Dohme Corp. TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
JP6629486B2 (ja) 2016-09-02 2020-01-15 スヴェン・ライフ・サイエンシズ・リミテッド ムスカリンｍ１受容体陽性アロステリックモジュレーター

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2791533C2 (ru) * 2017-06-20 2023-03-09 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение

Also Published As

Publication number Publication date
JP2019504901A (ja) 2019-02-21
CA3014791A1 (en) 2017-08-24
IL261058A (en) 2018-10-31
PH12018501731A1 (en) 2019-06-17
WO2017143041A1 (en) 2017-08-24
MA44253A (fr) 2018-12-26
CL2018002335A1 (es) 2019-02-01
BR112018016689A2 (pt) 2019-02-12
CN109069491A (zh) 2018-12-21
EP3416639A4 (en) 2019-07-03
KR20180110132A (ko) 2018-10-08
US20210230180A1 (en) 2021-07-29
EP3416639B1 (en) 2022-06-08
AU2017221404A1 (en) 2018-08-23
US11111251B2 (en) 2021-09-07
MX2018009952A (es) 2018-11-29
EP3416639A1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
EA201891854A1 (ru) Положительные аллостерические модуляторы мускаринового ацетилхолинового рецептора m
CO2020006248A2 (es) Moduladores de la vía de estrés integrada
ECSP18089579A (es) Moduladores de la vía de estrés integrada
CO2020006227A2 (es) Moduladores de la vía de estrés integrada
UY37230A (es) Moduladores de la vía de estrés integrada
DK3474846T3 (da) Positive, allosteriske modulatorer af den muskarinske acetylcholinreceptor m4
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
UY37229A (es) Moduladores de la vía de estrés integrada
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CL2016003212A1 (es) Derivados de indolín-2-ona o pirrolo-piridín-2-ona.
NZ737399A (en) Ccr2 modulators
MA49752A (fr) Procédés de préparation de composés de pyrrolidine
EA201491530A1 (ru) Модуляторы рецепторов эстрогенов и их применение
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EA202191519A1 (ru) Модуляторы trex1
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CO2017012622A2 (es) Moduladores alostéricos positivos del receptor muscarínico m2
EA201892264A1 (ru) Производные тетрагидроизохинолина
BR112018016629A2 (pt) moduladores alostéricos positivos do receptor muscarínico de acetilcolina m4
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
CL2019002583A1 (es) Inhibidores duales de magl y faah.
EA201890684A1 (ru) Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1
EA201990399A1 (ru) Соединения, композиции и их применение